JAMA|2025|Anderer S
PMID: 40445594
14102 studies
OBJECTIVE: To assess time trends of and examine which sociodemographic and clinical characteristics are associated with continuous glucose monitoring (CGM) initiation in insulin-treated older adults with type 2 diabetes (T2D). RESEARCH DESIGN AND MET…
The Impact of Weight on Daily Activities Questionnaire (IWDAQ) is a patient-reported outcome measure that uses a novel, adaptive design to assess the limitations in daily activities that are most important to individuals attempting to lose weight. Du…
The precise mechanism of action of semaglutide in obese patients remains uncertain, although it is evident that the drug confers a significant cardiac benefit. An excessively high-fat diet has been demonstrated to result in an increased expression of…
INTRODUCTION: An estimated 74.6% of Kuwaiti adults are classified as overweight or obese. As a result, Glucagon-like peptide 1 receptor agonists (GLP-1 RA) injections such as, Semaglutide, Liraglutide, and Tirzepatide have become an increasingly popu…
Heart failure (HF) affects 6 million people in the US, and type 2 diabetes (T2D) is a significant risk factor for HF. Since 2008, regulatory agencies have required cardiovascular safety trials for new T2D therapies, and these have consistently demons…
Recent trials underscore the cardiovascular (CV), renal, and metabolic benefits of semaglutide in individuals with and without type 2 diabetes (T2D). In T2D, semaglutide enhances glycemic control, reduces major adverse CV events (MACE), and slows chr…
INTRODUCTION: Dulaglutide and semaglutide are once-weekly administered GLP-1 receptor agonists (GLP-1 RAs) indicated for the treatment of hyperglycemia in individuals with type 2 diabetes mellitus (T2DM) and obesity (BMI ≥ 30 kg/m). OBJECTIVE: To eva…
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a chronic disease that substantially increases morbidity and mortality through its cardiovascular and renal complications. Beyond mere glycemic control, current guidelines from the European Society of…
OBJECTIVE: The objective of this study is to examine real-world dose titration patterns of semaglutide for weight management (Wegovy, Novo Nordisk A/S) in US adults and identify characteristics associated with early discontinuation. METHODS: We ident…
During treatment intensification of injectable therapies among persons with type 2 diabetes mellitus (T2DM) without evidence of severe insulin deficiency, a glucagon-like peptide-1 agonist (GLP-1 RA) is preferred to insulin. However, due to its progr…
Thanks to biochemical engineering, the glucagon-like peptide-1 (GLP-1) molecule has emerged as an essential element in the development of diverse agonists and multiagonists, based in the GLP-1 structure for obesity treatment. These new antiobesity me…
INTRODUCTION AND OBJECTIVES: There is still limited evidence on the role of glucagon-like peptide-1 receptor agonists in heart failure. We analyzed the efficacy in terms of health status, and the change in body weight of once-weekly semaglutide in pa…
With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al.demonstrated that semaglutide improved walking capacity and hemodynamic parameters an…
BACKGROUND: While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in reducing complications following total knee and hip arthroplasty, their effects in spinal surgery remain unclear. Prior studies have reported mixed…
Inflamed epicardial fat (EAT) accumulation around the myocardium and coronaries is a risk factor for cardiovascular disease. Glucagon-like peptide receptor-agonists 1 improves the insulin response and reduces EAT thickness. We aimed to demonstrate th…
Obesity affects approximately one in five U.S. adolescents. Although an increasing number of medications are approved for adolescent obesity as an adjunct to health behavior and lifestyle treatment, national data on the prevalence and correlates of o…